WithdrawnNot Applicable

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

Stopped: Funding did not come through as the product was sold to another company.

India0Started 2010-12

Plain-language summary

Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Should be willing to participate in the trial.
✓. Age less than 55 years.
✓. Best corrected visual acuity (BCVA) score of at least 5 letters (20/200), as assessed by ETDRS chart.
✓. Myopia of ≥ 6 Diopters.
✓. Fluorescein angiographic documentation of CNV.

Visual Acuity

Timeframe: 12 months

NCT IDNCT01218230

SponsorL.V. Prasad Eye Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-07